Intellipharmaceutics International Valuation
Is I4AA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of I4AA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: I4AA (€0.04) is trading below our estimate of fair value (€0.4)
Significantly Below Fair Value: I4AA is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for I4AA?
Other financial metrics that can be useful for relative valuation.
What is I4AA's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$1.92m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.1x |
Enterprise Value/EBITDA | -1.5x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does I4AA's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3x | ||
B8F Biofrontera | 0.7x | n/a | €22.3m |
SBX SynBiotic | 5.4x | 33.8% | €44.5m |
APPH Apontis Pharma | 1.9x | 17.7% | €68.8m |
ECX Epigenomics | 4.1x | 59.1% | €1.4m |
I4AA Intellipharmaceutics International | 2.1x | n/a | €2.6m |
Price-To-Sales vs Peers: I4AA is good value based on its Price-To-Sales Ratio (2.1x) compared to the peer average (3x).
Price to Earnings Ratio vs Industry
How does I4AA's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
Price-To-Sales vs Industry: I4AA is good value based on its Price-To-Sales Ratio (2.1x) compared to the European Pharmaceuticals industry average (3.3x).
Price to Sales Ratio vs Fair Ratio
What is I4AA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.1x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate I4AA's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.